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Objective: The aim of this study was to quantify, by modeling, the impact of significant 
  predictors on CD4 cell response during antiretroviral therapy in a resource-limited setting.
Methods: Modeling was used to determine which antiretroviral therapy response predictors 
(baseline CD4 cell count, clinical state, age, and adherence) significantly influence immuno-
logical response in terms of CD4 cell gain compared to a reference value at different periods 
of monitoring.
Results: At 6 months, CD4 cell response was significantly influenced by baseline CD4 count 
alone. The probability of no increase in CD4 cells was 2.6 higher in patients with a baseline 
CD4 cell count of $200/mm3. At 12 months, CD4 cell response was significantly influenced 
by both baseline CD4 cell count and adherence. The probability of no increase in CD4 cells 
was three times higher in patients with a baseline CD4 cell count of $200/mm3 and 0.15 times 
lower with adherent patients. At 18 months, CD4 cell response was also significantly influenced 
by both baseline CD4 cell count and adherence. The probability of no increase in CD4 cells 
was 5.1 times higher in patients with a baseline CD4 cell count of $200/mm3 and 0.28 times 
lower with   adherent patients. At 24 months, optimal CD4 cell response was significantly influ-
enced by adherence alone. Adherence increased the probability (by 5.8) of an optimal increase 
in CD4 cells. Age and baseline clinical state had no significant influence on immunological 
response.
Conclusion: The relationship between adherence and CD4 cell response was the most signifi-
cant compared to that of baseline CD4 cell count. Counseling before initiation of treatment and 
educational therapy during follow-up must always help to strengthen adherence and optimize 
the efficiency of antiretroviral therapy in a resource-limited setting.
Keywords: antiretroviral therapy, CD4 cells response, adherence, predictors, modeling, 
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Introduction
According to a United Nations report on human immunodeficiency virus (HIV)/
acquired immune deficiency syndrome (AIDS) in 2009, sub-Saharan Africa still bears 
an inordinate share of the HIV global burden.1 Although the rate of new HIV infec-
tions has decreased, the total number of people living with HIV/AIDS (PLWHAs) 
continues to rise.1 A CD4 cell count is recommended in practice for developing 
countries to monitor PLWHAs as it enables better decisions on the appropriate time to 
begin highly active antiretroviral therapy (HAART). CD4 cell count is also essential 
in monitoring the treatment, and it remains the best factor for predicting the occur-
rence of HIV-related complications.2 However, there is risk in only using CD4 cell 
count in patients on antiretroviral therapy (ART) without virological monitoring in 
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  resource-limited settings. While most predictors of ART are 
known, their quantitative impact on the field immunologi-
cal response is not. For the present study, immunological 
response was quantified by an increase in CD4 cells compared 
to the baseline CD4 cell count.
According to the World Health Organization, the defi-
nitions of clinical, immunological, and virological failure 
currently used in different settings represent different bio-
logical endpoints. It is not clear which criteria are optimal, 
as either individual measures or a combination of measures.3 
Several international recommendations based on clini-
cal studies found thresholds close to an optimal CD4 cell 
gain that could be achieved in 6 months or annually during 
an effective ART. The first 6 months of ART is a critical 
period for the future and should be given special attention.4 
  Immunological response failure can be described by a CD4 
cell gain of ,100/mm3 from the initiation of treatment,5 
and it is often associated with a poor immune recovery 
(CD4 cell count ,200/mm3).3 Functional immunological 
failure is defined by The World Health Organization – 
among other acceptable definitions – as a CD4 cell count 
of ,100 cells/mm3 after 6 months of treatment or a return 
to the level of CD4 cell count before the start of treatment 
(or a fall below this level) after 6 months of treatment. The 
immunological response in an effective ART is judged by 
an increase in CD4 cells of 150–200/mm3 in the first year 
and then more progressively.4 An adequate immunological 
response for most patients under treatment is defined as an 
increase in CD4 cells of 50–150/mm3 per year, generally 
with quicker response during the first 3 months.6 Subsequent 
increases in patients with good virological control showed 
an average increase of about 50–100 cells/mm3 per year for 
subsequent years until a steady level is reached.7
A CD4 cell count equal to 200/mm3 is the key   threshold 
value below which the risk of disease progression is increased 
significantly.3 Although it is never too late to start ART, 
it is better to start before the CD4 cell count drops below 
200/mm3.3 Data from several cohorts of asymptomatic 
patients, for example, converge to show that disease progres-
sion is accelerated in those of them who begin ART when 
their CD4 cell count is ,200/mm3.8–12 This is also supported 
by long-term data from several observational studies evaluat-
ing early ART (.200 cells/mm3) compared to delayed treat-
ment (,200 cells/mm3).13–16 Several clinical trials have also 
demonstrated the benefit of the introduction of ART, both 
in terms of survival and in reducing disease progression in 
patients with CD4 cell counts of ,200/mm3.17 In advanced 
disease (AIDS stage or CD4 cell count of ,200/mm3), life 
expectancy is shorter, justifying the recommendation of ART 
at this stage.4 The consequences of incomplete adherence 
of ART in raising the morbidity, mortality, and risk of drug 
resistance have long since been highlighted.18,19 Treatment 
success is related to a very high level of adherence at the ini-
tiation of treatment, but also over time. A review of the effec-
tiveness of ART in 24 studies related to interventions about 
adherence and published between 1996 and 2004, showed 
the best results were obtained when these interventions were 
targeted to people with poor adherence.20   Adherence remains 
a major concern in optimizing the response of ART in both 
industrialized countries and in developing countries. Age is 
also a risk factor for delayed treatment and less response to 
treatment. The increase of CD4 cells is usually slower and 
incomplete in the elderly and/or in those whose immuno-
suppression has been profound and prolonged.3 The risk 
of progression is more rapid in patients starting treatment 
after 50 years of age.10 Patients aged $50 years have a 
lower immunological response to treatment despite a good 
virological response.18,21
Some studies devoted to modeling ART response from 
taxonomy of CD4 count trajectories revealed several deter-
minants influencing the field immunological response in 
Cote d’Ivoire,22–24 which included age, clinical stage, base-
line CD4 cell count, and adherence. These parameters are 
not exhaustive, but are the predictors that were considered 
in the present study. The extent of CD4 cell count recovery 
varies during ART, despite suppression of the viral load. The 
clinical implication of this conundrum is important because 
suboptimal CD4 cell count recovery is associated with an 
increased risk of disease progression.25–29
In the absence of viral load in routine management 
of PLWHAs during ART in resource-limited settings, 
it’s important to analyze determinants of immunological 
response. As mentioned previously, the real quantitative 
impact of ART response predictors on the field immuno-
logical response has not been established. Therefore it’s 
important to evaluate the real quantitative impact of these 
predictors on various CD4 cells responses in terms of optimal, 
suboptimal, or absence of CD4 cell increase. Cote d’Ivoire 
modeling studies in bioclinical and therapeutic monitoring 
of patients are rare. The modeling stage in clinical research 
is fundamental because the mathematical models can be 
used to summarize the situation and try to supply rigorous 
(ie, statistically significant) answers, which can ensure the 
efficiency of ART in resource-limited countries. Therefore, 
the aim of the present study was to use modeling to determine 
which ART response predictors (baseline CD4 cell count, 
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clinical state, age, and adherence) significantly influence 
immunological response in terms of CD4 cell gain compared 
to a reference value at different periods of monitoring in a 
resource-limited setting.
Methods
Patients and biomedical data
The biomedical data underlying this model are from a 
  longitudinal observational database of bioclinical and thera-
peutic monitoring of outpatients on antiretroviral therapy. 
This study is consistent with the ethical aspects related to 
patients during their follow-up with a noninvasive method 
for the collection of medical and therapeutic data. Data are 
from the routine monitoring of patients with prior approval 
from the administrative health authority. The observational 
databases are suitable for any modeling. Indeed, these data-
bases showing long-term monitoring of patients has the 
undisputed advantage of measuring the reality of the disease, 
with consideration of patient care in routine clinical practice. 
This observational study was conducted in clinical centers 
accredited in the care of PLWHAs in Abidjan: Unit of Ambu-
latory Care and Advice (USAC) and the Center for Integrated 
Bioclinical Research of Abidjan (CIRBA). This clinical study 
was carried out on HIV-infected outpatients, which included 
HIV-positive men and women (irrespective of HIV type) 
aged $15 years who were antiretroviral-naive (had no history 
of antiretroviral use) and were prescribed triple drug antiret-
roviral therapy at enrolment in the drug treatment program 
between 2007 and 2008. Study subjects were followed during 
24 months of therapy by their regular physician in routine 
clinical practice. According to the immunological and clinical 
criteria (Centers for Disease Control and Prevention [CDC] 
classification 1993)30 and eligibility to antiretroviral therapy 
for adolescents and adults in Cote d’Ivoire,31 asymptomatic 
patients with a CD4 cell count of ,200/mm3, symptomatic 
patients (CDC stage B) with a CD4 cell count of ,350/mm3, 
and AIDS-symptomatic patients (CDC stage C) irrespective 
of CD4 cell count were considered. The follow-up period 
was limited to 24 months. Adherence was assessed every 
3 months with low-cost methods (interviewing and keeping 
of medical appointments – including appointments at the 
pharmacy to replenish antiretroviral drugs) in a resource-
limited setting. Treatment adherence was assessed by the 
patients’ regular physician. A general analysis on the review 
of access to ART in Cote d’Ivoire confirmed that the most 
common methods of assessing adherence are the keeping of 
appointments and interviewing patients during consultations 
or prescription refills at the pharmacy.32 CD4 cell counts 
were determined by flow cytometry (FACSCalibur; Becton 
Dickinson, Franklin Lakes, NJ). A baseline CD4 cell count 
not only guides the decision on when to initiate ART but is 
also essential if CD4 cell counts are to be used to monitor 
ART, particularly in resource-limited settings. Outpatients 
eligible for ART without a baseline CD4 cell count were not 
included in the study. Subjects who had at least four CD4 
cell count measurements after 2 years of HAART initiation 
were included.
Multivariate logistic regression model
Routine monitoring of post-HAART CD4 cell counts is 
recommended every 6 months in resource-limited settings. 
Therefore, the post-HAART follow-up periods selected were: 
M6 (at 6 months), M12 (at 12 months), M18 (at 18 months), 
and M24 (at 24 months). CD4 cell gain was determined from 
the baseline CD4 cell count at M0 (prior to initiation of treat-
ment). Baseline CD4 cell count was defined as the pre-HAART 
measurement of CD4 cell count after enrolment of the patient 
in the drug treatment program. CD4 cell gain for each patient 
was determined as the difference between CD4 cell count at 
each post-HAART follow-up period and the individual base-
line CD4 cell count. The general equation of the model was:
  R(t) = β0 + β1clin + β2CD4 + β3age + β4adher(t) + ε, (1)
where R(t) is the immunological response within the moni-
toring period t, clin is the baseline CDC clinical stage, CD4 
is the baseline CD4 cell count, age is the patient’s age at 
initiation of treatment, adher(t) is adherence at the monitoring 
period t, and ε is the error term. The equation is a model on 
immunological response in terms of CD4 cell gain depen-
dent on adherence and other predictors of ART response. 
The strength of relationship between these parameters and 
the antiretroviral response was estimated (coefficients esti-
mated by the model are mathematically related to the odds 
ratio). A multinomial logistic regression was conducted 
using Stata® (v 9; StataCorp LP, College Station, TX). The 
dependent variable is the immunological response to ART 
within monitoring period t (R[t]). The regression model 
was multinomial because three modalities for R(t) were 
chosen: R2 (coded two), optimal immunological response; 
R1 (coded one), suboptimal immunological response; and 
R0 (coded zero), stabilization or decrease of CD4 cell count 
compared to the baseline value. A reference value of CD4 cell 
gain was chosen at each follow-up period. With an optimal 
immunological response, CD4 cell gain must be higher than 
this reference value. A suboptimal immunological response 
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was equivalent to a CD4 cell gain below the reference value, 
but not zero. At each follow-up period, a type of immunologi-
cal response was considered by the software as a reference. 
Each explanatory variable as an ART response predictor 
had two modalities: compared to a good immunological 
response, the first modality was coded zero (unfavorable) 
and the second was coded one (favorable). The significance 
threshold for the multivariate analysis was 5% (ie, P , 0.05). 
Descriptions of codes, values, and modalities of the different 
variables are presented in Tables 1 and 2.
Results
Baseline characteristics and adherence
The study was based on a total of 403 individuals (160 men 
and 243 women). At baseline the median age was 40 years 
(interquartile range: 33–47). Patients eligible for treat-
ment were mainly symptomatic (CDC stage B) with a 
CD4 cell count of ,350/mm3. A baseline CD4 cell count 
of ,200/mm3 was higher among patients with a median of 
137/mm3 (interquartile range: 64–211). The antiretroviral 
regimen was predominantly composed of an association 
between two nucleoside reverse transcriptase inhibitors plus 
one nonnucleoside reverse transcriptase inhibitor: of the 
403 study subjects, 374 (92.8%) patients initiated therapy 
with a nonnucleoside reverse transcriptase inhibitor-based 
regimen. Of those 374 patients, 240 (64.17%) used nevirapine 
and 134 (35.83%) used efavirenz. Adherence was lowest at 
M24. All the baseline characteristics of patients are presented 
in Table 3.
Multinomial logistic regression analysis
The model was globally significant at M6 (P = 0.04), M12 
(P = 0.0053), M18 (P = 0.0008), and M24 (P , 0.0001). 
The explanatory variables combined influence the immu-
nological response at the different monitoring periods. 
However, some observations may influence the model alone. 
Therefore, in order to judge the quality of the model fit to 
data collected, it was important to analyze remainders in 
order to detect poorly modeled observations. The analysis 
showed that these various observations did not significantly 
affect the model.
Quantitative impact of significant 
predictors on various CD4 cell  
response at different periods of follow-up
At M6, the model (P = 0.04) and the coefficient of baseline 
CD4 cell count (P = 0.001) were significant. Baseline CD4 
cell count significantly influenced the ART response. The 
equation of the immunological response was:
  Ln[P(R0)/P(R2)] = −1.3 + 0.94 × CD4  (2)
The probability of having no CD4 cell gain compared to a 
gain of $100/mm3 was influenced at M6 by the baseline CD4 
cell count, ie, it was 2.6 higher in patients with a baseline 
CD4 cell count of $200/mm3 than those with a baseline CD4 
cell count of ,200/mm3 at M6 (Table 4).
At M12, the model (P = 0.0053) and the coefficients 
of baseline CD4 cell count (P = 0.003) and adherence 
(P , 0.001) were significant. Adherence and baseline CD4 
cell count significantly influenced ART response. The 
  equation of the immunological response was:
Ln[P(R0)/P(R2)] = 0.06 + 1.1 × CD4 – 1.90 × adher(M12) 
  (3)
The probability of having no CD4 cell gain compared to 
a gain of $150/mm3 was influenced at M12 by both baseline 
CD4 cell count and adherence, ie, it was three times higher 
in patients with a baseline CD4 cell count of $200/mm3 
than those with a baseline CD4 cell count of ,200/mm3 
and 0.15 times less higher with adherent patients than with 
nonadherent ones at M12 (Table 4).
At M18, the model (P = 0.0008) and the coefficients 
of baseline CD4 cell count (P , 0.01) and adherence 
(P = 0.022) were significant. Adherence and baseline CD4 
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Table 1 Codes, values, and description of dependent variables at different periods of medical follow-up
Follow-up  
period
Expression and code of immunological response
Optimal immunological  
response 
R2 = 2
Suboptimal immunological  
response 
R1 = 1
Stabilization or decrease of CD4 cell  
count compared to the baseline value 
R0 = 0
M6 CD4 cell gain $ 100/mm3 CD4 cell gain , 100/mm3 Absence of CD4 cell gain
M12 CD4 cell gain $ 150/mm3 CD4 cell gain , 150/mm3 Absence of CD4 cell gain
M18 CD4 cell gain $ 200/mm3 CD4 cell gain , 200/mm3 Absence of CD4 cell gain
M24 CD4 cell gain $ 250/mm3 CD4 cell gain , 250/mm3 Absence of CD4 cell gain
Abbreviations: M6, 6 months; M12, 12 months; M18, 18 months; M24, 24 months.Patient Preference and Adherence 2012:6
cell count significantly influenced ART response. The 
  equation of the immunological response was:
Ln[P(R0)/P(R1)] = −0.95 + 1.63 × CD4 – 1.27 × adher(M18) 
  (4)
The probability of having no CD4 cell gain compared to 
a gain of ,200/mm3 at M18 was influenced by both baseline 
CD4 cell count and adherence, ie, it was 5.1 times higher in 
patients with a baseline CD4 cell count of $200/mm3 than 
in those with a baseline CD4 cell count of ,200/mm3 and 
0.28 times lower with adherent patients than with nonadher-
ent ones at M18 (Table 5).
At M24, adherence and baseline CD4 cell count signifi-
cantly influenced ART response. The model (P , 0.0001) 
and the coefficients of baseline CD4 cell count (P = 0.037) 
and adherence (P = 0.023) were significant in modeling the 
response R0 in relation to response R1. The equation of the 
immunological response was:
Ln[P(R0)/P(R1)] = −0.90 + 0.99 × CD4 – 1.12 × adher(M24) 
  (5)
The probability of having no CD4 cell gain compared 
to a gain of ,250/mm3 was influenced by both baseline 
CD4 cell count and adherence at M24. Moreover, by mod-
eling the response R2 in relation to response R1, the model 
remained significant (P , 0.0001), but only the coefficient 
of adherence was significant (P , 0.001). The equation of 
the immunological response was then:
  Ln[P(R2)/P(R1)] = 1.98 + 1.76 × adher(M24)  (6)
The probability of having a CD4 cell gain of $250/mm3 
compared to a gain of ,250/mm3 was only influenced by 
adherence at M24. The likelihood of having no CD4 cell gain 
compared to a gain of ,250/mm 3 was 2.7 times higher in 
patients with a baseline CD4 cell count of $200/mm3 than 
those with a baseline CD4 cell count of ,200/mm3 and 
0.3 times lower with adherent patients than with nonadherent 
ones. Adherence alone (P , 0.001) increased the probability 
(by 5.8) of having a CD4 cell gain of $250/mm3 compared 
to a gain of ,250/mm3 (Table 5).
Discussion
The ultimate goal of HAART is the reconstitution of the 
immune system by viral suppression and obtaining a CD4 
cell count that protects optimally against opportunistic infec-
tions and HIV-related cancers.33 In patients with a sustained 
reduction in viral load, CD4 cell counts increase for at least 
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Table 2 Codes, values, and description of explanatory variables
Explanatory variables Modality and codes
Baseline CDC clinical stage Stage C: 0 
Stages A and B: 1
Baseline CD4 cell count ,200/mm3: 0 
$200/mm3: 1
Age at treatment initiation .50 years: 0 
#50 years: 1
Adherence at different periods of medical 
follow-up
Incomplete adherence: 0 
Good adherence: 1
Abbreviation: CDC, Centers for Disease Control and Prevention.
Table 3 Patients’ baseline characteristics and adherence
Age at treatment initiation
  Median (IQR) 40 (33–47)
  .50 years 61 (15.14)
  #50 years 342 (84.86)
Female 243 (60.3)
HIV type
  HIV1 377 (93.5)
  HIV2 11 (2.7)
  HIV dual 15 (3.7)
Karnofsky score median (IQR) 90 (90–100)
Groups of eligible patients for ART
    Asymptomatic patients with CD4 cell count  
of ,200/mm3
31 (7.69)
    Symptomatic patients (CDC stage B) with CD4  
cell count of ,350/mm3
273 (67.74)
    Symptomatic patients (CDC stage C) irrespective  
of CD4 cell count
99 (24.57)
Baseline CDC clinical stage
  Stages A and B 304 (75.43)
  Stage C 99 (24.56)
Baseline CD4 cell count/mm3
  Median (IQR) 137 (64–211)
  ,200 291 (72.2)
  $200 112 (27.8)
Presence of opportunistic infections 207 (51.4)
ART regimens
  NNRTI-based regimen 374 (92.8)
  PI-based regimen 23 (5.6)
  3 NRTIs regimen 6 (1.5)
Patients with cotrimoxazole prophylaxis 377 (93.5)
Good adherence to ART
  M6 383 (95)
  M12 364 (90.32)
  M18 375 (93)
  M24 350 (86.8)
Note: Data presented as n (%) unless otherwise stated. 
Abbreviations: ART, antiretroviral therapy; CDC, Centers for Disease Control 
and  Prevention;  HIV,  human  immunodeficiency  virus;  IQR,  interquartile  range; 
M6, 6 months; M12, 12 months; M18, 18 months; M24, 24 months; NRTI, nucleoside 
reverse  transcriptase  inhibitor;  NNRTI,  nonnucleoside  reverse  transcriptase 
inhibitor; PI, protease inhibitor.Patient Preference and Adherence 2012:6
3–5 years after initiation of treatment. The initial increase in 
CD4 cells within 3–6 months is usually rapid and is followed 
by a second phase of slowing growth rates approaching a 
stable CD4 cell count at 4–6 years.7,34 Other authors have 
noted a significant increase in CD4 cell count during the 
first 2 years after starting HAART, followed by stabiliza-
tion between 2–3.5 years.35 This suggests the existence of a 
change in slope of the trajectory of CD4 cell count at about 
2 years after starting treatment, reaching a straight line.
The present study of the determinants of immunological 
response was significant because, according to the studies 
mentioned above, the first 2 years are critical for obtaining 
a substantial increase in CD4 cell count after initiation of 
  treatment. Using a logistic regression model, baseline CD4 
cell count and adherence were identified as factors sig-
nificantly associated with immunological response during 
the first 24 months of treatment. The results showed that 
a   substantial increase in CD4 cells during ART was most 
notable in patients with a weaker baseline CD4 cell count 
(,200/mm3). However, this does not mean that the therapeu-
tic response was not positive in patients with baseline CD4 
cell counts that were $200/mm3; but obtaining the optimal 
CD4 cell gain was less likely. The probability of having no 
CD4 cell gain was progressively lower over time among 
adherent patients. At M24, obtaining the optimal CD4 cell 
gain was almost six times higher among adherent patients in 
Abidjan compared to a suboptimal gain of CD4 cells. Based 
on the present analysis, it can be considered that a patient 
who begins ART with a lower baseline CD4 cell count 
(,200/mm3) is able to obtain the optimal CD4 cell gain, of 
course by maintaining good adherence throughout the first 
24 months of treatment. Patients in the present study with a 
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Table 4 Odds ratio representing relative risks of response R0 or R1 compared to response R2 at 6-month and 12-month follow-up 
period
Follow-up  
period
Favorable variables Reference Response R0
a Response R1
a
OR 95% CI P OR 95% CI P
M6 Age #50 years 
Stages A or B 
Baseline CD4 cell count  
of $200/mm3 
Good adherence
Age .50 years 
Stage C 
Baseline CD4 cell count  
of ,200/mm3 
Incomplete adherence
1.28 
0.91 
 
2.57 
0.70
0.57–2.86 
0.47–1.76 
 
1.44–4.57 
0.20–2.41
0.542 
0.782 
 
0.001 
0.576
1.44 
0.98 
 
0.78 
0.76
0.76–2.72 
0.58–1.63 
 
0.46–1.32 
0.28–2.11
0.262 
0.932 
 
0.350 
0.603
M12 Age #50 years 
Stages A or B 
Baseline CD4 cell count  
of $200/mm3 
Good adherence
Age .50 years 
Stage C 
Baseline CD4 cell count  
of ,200/mm3 
Incomplete adherence
0.76 
0.76 
 
3 
0.15
0.30–1.94 
0.35–1.69 
 
1.45–6.26 
0.06–0.39
0.568 
0.509 
 
0.003 
,0.001
1.12 
1.08 
 
1.20 
0.53
0.62–2.02 
0.66–1.77 
 
0.75–1.94 
0.24–1.14
0.709 
0.747 
 
0.446 
0.105
Notes: aResponses R0 and R1 were compared to response R2; P , 0.05 was considered significant. 
Abbreviations: CI, confidence interval; OR, odds ratio; R0, stabilization or decrease of CD4 cell count compared to the baseline value; R1, suboptimal immunological 
response; R2, optimal immunological response.
Table 5 Odds ratio representing relative risks of response R0 or R2 compared to response R1 at 18-month and 24-month follow-up 
period
Follow-up  
period
Favorable variables Reference Response R0
a Response R2
a
OR 95% CI P OR 95% CI P
M18 Age #50 years 
Stages A or B 
Baseline CD4 cell count  
of $200/mm3 
Good adherence
Age .50 years 
Stage C 
Baseline CD4 cell count  
of ,200/mm3 
Incomplete adherence
0.91 
0.53 
 
5.14 
0.28
0.31–2.69 
0.22–1.29 
 
2.22–11.89 
0.09–0.83
0.867 
0.16 
 
,0.001 
0.022
1.19 
0.94 
 
1.14 
2.44
0.67–2.12 
0.58–1.51 
 
0.71–1.82 
0.93–6.38
0.550 
0.794 
 
0.587 
0.070
M24 Age #50 years 
Stages A or B 
Baseline CD4 cell count  
of $200/mm3 
Good adherence
Age .50 years 
Stage C 
Baseline CD4 cell count  
of ,200/mm3 
Incomplete adherence
0.53 
0.45 
 
2.71 
0.32
0.17–1.62 
0.17–1.19 
 
1.06–6.94 
0.12–0.86
0.267 
0.107 
 
0.037 
0.023
0.97 
0.96 
 
0.82 
5.82
0.54–1.76 
0.58–1.58 
 
0.50–1.32 
2.24–15.14
0.931 
0.873 
 
0.413 
,0.001
Notes: aResponses R0 and R2 were compared to response R1; P , 0.05 was considered significant. 
Abbreviations: CI, confidence interval; OR, odds ratio; R0, stabilization or decrease of CD4 cell count compared to the baseline value; R1, suboptimal immunological 
response; R2, optimal immunological response.Patient Preference and Adherence 2012:6
higher baseline CD4 cell count ($200/mm3) had a relatively 
lower CD4 cell gain. It has been found in previous studies 
that patients with a significant increase in CD4 cell count 
in the preceding period had a smaller increase in the fol-
lowing period and vice versa, suggesting a manifestation of 
regression toward the mean and a ceiling effect for patients 
approaching the normal range of CD4 cell count.33 These 
results are similar to those reported by other studies in Africa, 
where patients with low CD4 cell counts had a high level of 
increase in CD4 cells.36,37
At M6, the baseline CD4 cell count was the only vari-
able significantly correlated with immunological response. 
Kitahata et al noted improved outcomes 6 months after ini-
tiation of HAART at all levels of baseline CD4 cell count;38 
but in the present study, patients with a baseline CD4 cell 
count of $200/mm3 had a stabilized or decreased CD4 cell 
count at M6 and they were, therefore, less likely to obtain the 
optimal CD4 cell gain. However, knowing that the baseline 
CD4 cell count may correspond to relatively high values, 
the immunological response may be considered positive if the 
CD4 cell count varies slightly or stabilizes at relatively high 
values. Since the majority of patients in Cote d’Ivoire start 
treatment with a relatively low CD4 cell count (,350/mm3) or 
at an advanced stage, it is important, nonetheless, to aim for 
an optimal CD4 cell gain in the first critical months of ART. 
Many AIDS-defining events occur in the first 6 months.39–41 
In the present study, suboptimal CD4 cell gain was below 
100/mm3 at M6. Other studies saw a ,50/mm3 increase in 
CD4 cell count after 6 months of ART as suboptimal.36,37,42,43 
It has been shown in an urban cohort on ART in sub-Saharan 
Africa that the majority of patients with a suboptimal CD4 
cell gain after 6 months still showed a suboptimal CD4 cell 
gain at 12 months despite supported viral suppression.37 As 
patients with a suboptimal gain of CD4 cells at 6 months are 
likely to maintain the phenomenon, they may need to evaluate 
the recovery of immune function, especially in Africa where 
there is an increased risk of opportunistic infections. It is 
possible that CD4 cells do not recover both in optimum rate 
and function that is required for activation of T-lymphocytes 
in Africans due to frequent infections by various endemic 
pathogens in the region.44–46
At M12, baseline CD4 count and adherence were the 
two variables significantly correlated with immunological 
response. The interpretation is identical to that of M6 with 
respect to the relationship between a baseline CD4 cell count 
of $200/mm3 and the absence of optimal CD4 cell gain. 
But would it make sense to compare this finding to a lower 
adherence of patients with a high baseline CD4 cell count? A 
lower baseline CD4 cell count and prior diagnosis of AIDS 
have been previously associated with better adherence.47 
Others have also found that advanced stage was associated 
with increased adherence of treatment,48 while others have 
reported an inverse relationship49 or no association with 
CD4 cell count.50
At M18 and M24, absence of CD4 cell gain was cor-
related with a baseline CD4 cell count of $200/mm3. And 
more importantly, this lack of CD4 cell gain was compared to 
obtaining a suboptimal CD4 cell gain, suggesting that obtain-
ing the optimal CD4 cell gain is even less likely for patients 
with a relatively high baseline CD4 cell count ($200/mm3) 
at M18 and M24. Dragsted et al, using the EuroSIDA cohort, 
studied predictors of immunological failure after initial 
response to HAART with patients who achieved a CD4 
cell gain of .100/mm3 between 6–12 months.51 Among the 
three factors significantly associated with the occurrence of 
immunological failure in their study, there appeared a higher 
number of CD4 cell counts before treatment. By defining 
their immunological failure as the occurrence of a CD4 
cell count inferior to or the same value as before treatment, 
this confirms, as in the present study, the correlation of the 
absence of optimal CD4 cell gain with a higher baseline CD4 
cell count. This study had the assumption that when CD4 cell 
count was well above 200/mm3, the threshold of decline in 
CD4 cell count was higher and the clinician was not prompted 
to change treatment quickly for fear of recurrence of pro-
found immune deficiency. This was confirmed by the fact 
that changes in treatment occurred prematurely in patients 
whose CD4 cell counts were lower before the treatment.51 
In another study, a high baseline CD4 cell count was also 
associated with the occurrence of immunological failure.52 
Wu et al reported on the relationships of baseline indices and 
virological responses to multiple CD4 cell kinetic patterns.53 
They observed a negative relationship between baseline CD4 
cell count and the magnitude of CD4 cell restoration. Hill 
et al had earlier observed that discordant CD4 cell responses 
to HAART were significantly more common in patients with 
higher baseline CD4 cell counts.54
At M24, good adherence was strongly and uniquely asso-
ciated with obtaining the optimal CD4 cell gain ($250/mm3) 
compared with a suboptimal CD4 cell gain (,250/mm3). 
Other authors considered a suboptimal CD4 cell gain as less 
than 200/mm3 after 24 months.37 Kulkarni et al sought to 
determine whether baseline CD4 cell count also influenced 
immune reconstitution as measured by CD4 cell counts 
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  during HAART.55 They defined baseline CD4 cell count as 
the first CD4 cell count measurement after diagnosis of HIV 
infection, while it was defined in the present study as the 
pre-HAART measurement of CD4 cell count. Kulkarni et al 
developed a novel marker, the nadir/baseline ratio, to have a 
high degree of association with a future course of immune 
reconstitution after HAART. They excluded subjects that 
never reached VL suppression or had an AIDS event after 
HAART. But it would be difficult to confirm this correla-
tion between the new marker and the field immunological 
response in resource-limited settings. Patients in poor settings 
were often enrolled at an advanced stage of the disease in 
the treatment program, and confirmation of viral suppression 
was virtually impossible because of the unavailability of viral 
load in routine practice. In addition, the level of adherence 
varied greatly between patients. Their study was conducted 
in resource-rich settings with high rates of adherence in the 
cohort studied and access to early postinfection CD4 cell 
counts. They excluded subjects that never reached viral 
load suppression or had an AIDS event after HAART. Poor 
adherence is seriously affecting the long-term effectiveness 
of the current available treatments.56 Adherence is the key to 
a long-term benefit in these patients, who should be moni-
tored and supported by a rigorous and rapid management of 
side effects.57
In the present study, adherence emerged as an important 
predictor of immunological response. Another study deter-
mined the relationship between adherence and immunoviro-
logical response and the results demonstrated the difficulties 
of adherence to ART in Abidjan.58 The problem of adherence 
is supported by a series of studies in Africa,59–64 in which the 
lowest rate was observed in Cote d’Ivoire. Indeed, Eholie 
et al found a low level of adherence in Ivorian patients and 
noted that adherence to HAART in Cote d’Ivoire is a more 
critical issue than previously reported.64 It is important to 
optimize adherence because it is essential to successful 
treatment. Age at initiation of therapy and the baseline 
clinical state did not have significant influence on ART 
immunological response at different periods of monitoring 
in Abidjan. Lifson et al analyzed the CD4 count trajectory 
after HAART initiation and showed that multiple factors 
may influence this immunological response, including a 
preceding AIDS diagnosis.65 But their study was related 
to the long-term CD4 count response. As in the present 
study, where an age limit of .50 years and another deal-
ing with younger patients to assess the influence of age on 
ART response were considered, other authors also found 
that age was not a significant predictor of immunological 
response to ART in both the urban cohort in sub-Saharan 
Africa and in a United States cohort.37,66 In contrast, com-
parative studies in the United States showed an influence 
of age, with an   average annual gain in CD4 cell count of 
50/mm3 among subjects $50 years against an average of 
100/mm3 in the younger ones.67 Studies have also shown 
that an age of .30 years was associated with a suboptimal 
CD4 cell gain36,68 because it is correlated with the evolution 
of the thymus, which is necessary for adequate immune 
reconstitution.68,69 In general, studies have shown that the 
immunological response, closely linked to the regenerative 
capacity of the thymus, is less pronounced among the elderly 
receiving ART.21,70,71 And the positive effect of young age 
on immune reconstitution has been repeatedly documented 
in studies of large cohorts.7,72–76
Conclusion
Among the predictors identified during ART, age and 
baseline clinical state did not have significant influence 
on immunological response in terms of CD4 cell gain in 
the present study. Baseline CD4 cell count and adherence 
influenced to varying degrees this immunological response. 
Patients in Cote d’Ivoire beginning treatment with a rela-
tively low baseline CD4 cell count can achieve the optimal 
CD4 cell gain during the first 24 months of follow up with 
good adherence. Even if it is less likely for patients with a 
higher baseline CD4 cell count to obtain the optimal CD4 
cell gain, maintaining relatively high CD4 cell counts during 
HAART is also possible with good   adherence. The strength 
of the relationship between adherence and CD4 cell response 
was the most significant compared to that of baseline CD4 
cell count during 24 months of ART in Abidjan (obtaining 
the optimal CD4 cell gain is almost six times higher among 
adherent patients when compared to a suboptimal gain 
of CD4 cells). Counseling before initiation  of ART and 
therapeutic education during follow-up must always help to 
strengthen adherence and optimize the efficiency of ART in 
resource-limited settings.
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